Edition:
United States

Novan Inc (NOVN.OQ)

NOVN.OQ on NASDAQ Stock Exchange Global Market

3.35USD
3:59pm EST
Change (% chg)

$0.03 (+0.90%)
Prev Close
$3.32
Open
$3.30
Day's High
$3.35
Day's Low
$3.27
Volume
2,205
Avg. Vol
23,460
52-wk High
$8.19
52-wk Low
$2.85

Chart for

About

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's... (more)

Overall

Beta: --
Market Cap(Mil.): $85.77
Shares Outstanding(Mil.): 25.99
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.22 16.52
EPS (TTM): -- -- --
ROI: -- 14.09 36.19
ROE: -- 15.56 17.38

BRIEF-Eugene Sun Appointed To Novan Board Of Directors

* EUGENE SUN APPOINTED TO NOVAN BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Feb 21 2018

BRIEF-Novan Announces First Patient Dosed In Phase 2 Molluscum Contagiosum Trial With SB206

* NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 MOLLUSCUM CONTAGIOSUM TRIAL WITH SB206

Jan 25 2018

BRIEF-Reedy Creek Investments Reports 26.4 Percent Stake In Novan Inc

* REEDY CREEK INVESTMENTS LLC REPORTS 26.4 PERCENT STAKE IN NOVAN INC AS OF JANUARY 9 - SEC FILING Source text : ( http://bit.ly/2DvfPeF ) Further company coverage:

Jan 22 2018

BRIEF-Novan Says Interim CFO William Hodges To Step Down

* NOVAN INC - WILLIAM L. HODGES, INTERIM CHIEF FINANCIAL OFFICER NOTIFIED THE CO OF HIS DECISION TO STEP DOWN EFFECTIVE JANUARY 19, 2018

Jan 19 2018

BRIEF-Novan Announces Pricing Of $38.0 Mln Offering Of Common Stock And Warrants

* NOVAN ANNOUNCES PRICING OF $38.0 MILLION OFFERING OF COMMON STOCK AND WARRANTS

Jan 05 2018

BRIEF-Novan Announces Proposed Public Offering Of Common Stock And Warrants

* NOVAN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Source text for Eikon: Further company coverage:

Jan 04 2018

BRIEF-Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414

* NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414

Dec 05 2017

BRIEF-Novan says ‍agreed to business structure to enable development of SB204 via 3rd party financing and execution

* Novan Inc -‍agreed to business structure to enable development of SB204 via 3rd party financing, 3rd party execution of additional Phase 3 pivotal trial​

Nov 07 2017

BRIEF-Novan acquires IP rights to treat viral malignancies with nitric oxide

* Novan acquires IP rights to treat viral malignancies with nitric oxide

Oct 18 2017

BRIEF-Novan Inc says files for mixed shelf of upto $150 million ‍​

* Novan Inc says files for mixed shelf of upto $150 million - SEC filing‍​ ‍​

Oct 02 2017

Earnings vs. Estimates